<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>83-AZITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering medication</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>83-AZITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the blood concentrations of ciclosporin and of the creatinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>83-AZITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>83-AZITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IVABRADINE" rxcui="77417">
<ATC code="C01EB17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of problems with ventricular rhythm, especially of torsades de pointes. In addition, increase of the plasm concentrations of the ivabradine due to decrease of its metabolism by the azithromycin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>83-AZITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolosis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>83-AZITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
</INTERACTIONS>
